- Home
- WLKP vs CAPR Comparison
WLKP vs CAPR Comparison
Compare WLKP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLKP
- CAPR
- Stock Information
- Founded
- WLKP 2014
- CAPR 2005
- Country
- WLKP United States
- CAPR United States
- Employees
- WLKP N/A
- CAPR N/A
- Industry
- WLKP Major Chemicals
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLKP Industrials
- CAPR Health Care
- Exchange
- WLKP Nasdaq
- CAPR Nasdaq
- Market Cap
- WLKP 833.7M
- CAPR 600.7M
- IPO Year
- WLKP 2014
- CAPR N/A
- Fundamental
- Price
- WLKP $22.46
- CAPR $10.25
- Analyst Decision
- WLKP
- CAPR Strong Buy
- Analyst Count
- WLKP 0
- CAPR 8
- Target Price
- WLKP N/A
- CAPR $33.75
- AVG Volume (30 Days)
- WLKP 31.9K
- CAPR 3.2M
- Earning Date
- WLKP 08-05-2025
- CAPR 08-06-2025
- Dividend Yield
- WLKP 8.40%
- CAPR N/A
- EPS Growth
- WLKP N/A
- CAPR N/A
- EPS
- WLKP 1.49
- CAPR N/A
- Revenue
- WLKP $1,088,852,000.00
- CAPR $17,363,588.00
- Revenue This Year
- WLKP $8.90
- CAPR $258.96
- Revenue Next Year
- WLKP $6.87
- CAPR $8.02
- P/E Ratio
- WLKP $15.07
- CAPR N/A
- Revenue Growth
- WLKP N/A
- CAPR N/A
- 52 Week Low
- WLKP $21.19
- CAPR $3.52
- 52 Week High
- WLKP $25.04
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- WLKP 50.63
- CAPR 47.85
- Support Level
- WLKP $21.96
- CAPR $9.45
- Resistance Level
- WLKP $22.45
- CAPR $11.58
- Average True Range (ATR)
- WLKP 0.28
- CAPR 1.44
- MACD
- WLKP 0.06
- CAPR -0.14
- Stochastic Oscillator
- WLKP 70.49
- CAPR 54.08
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.